Travis Murdoch, HI-Bio CEO
May 24, 2024 07:26 AM EDTUpdated 09:22 AM
R&D

HI-Bio out­lines da­ta that sparked $1.15B Bio­gen buy­out

Max Gelman

Senior Editor

Days af­ter get­ting ac­quired by Bio­gen, Hu­man Im­munol­o­gy Bio­sciences re­vealed Phase 2 da­ta that helped seal the deal.

In the tri­al, which looked at the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times